巴曲酶联合依达拉奉治疗急性脑梗死的临床观察

摘要

Objective:To observe the effect of batroxobin enzymes with edaravone for treatment of acute cerebral infarction. Method:To retrospectively analyze 45 cases who with acute cerebral infarction had lost thrombolysis opportunities. Result:The total efficiency and markedly effective rate of the combined group was significantly better than that of batroxobin group(P<0.05). Combination therapy did not affect the batroxobin defibrase role. Compared the two groups of neurological deficit scores before and after treatment,there were significantly lower(P<0.01). The combined group improved more significantly than batroxobin group(P<0.01). The incidences of adverse reactions of the two groups were few and mild. Conclusion:Batroxobin edaravone method can be effective in treating acute cerebral infarction,and significantly improve the patient’s neurological deficit.%　　目的：观察与分析巴曲酶联合依达拉奉治疗急性脑梗死的临床效果.方法：回顾性分析本院收治的45例已失去溶栓机会的急性脑梗死患者的临床资料.结果：联合组总有效率和显效率均明显优于巴曲酶组(P<0.05)；联合治疗并不影响巴曲酶的降纤作用；治疗前后比较两组的神经功能缺损评分都明显降低(P<0.01)，联合组比巴曲酶组获得的改善更显著(P<0.01)；两组发生不良反应均少而轻.结论：采用巴曲酶联合依达拉奉的方法可以有效治疗急性脑梗死，并能明显改善患者的神经功能损伤.